What is the price-to-earnings ratio of OncoCyte?
The price-earnings ratio of OncoCyte is currently 13.57.
OncoCyte P/S 2024
OncoCyte P/S
13.57
Ticker
OCX
ISIN
US68235C1071
WKN
A2ACBH
As of Jul 2, 2024, OncoCyte's P/S ratio stood at 13.57, a -41.46% change from the 23.18 P/S ratio recorded in the previous year.
The OncoCyte P/S history
OncoCyte Aktienanalyse
What does OncoCyte do?
OncoCyte Corp is a company based in Alameda, California, that is involved in the field of cancer diagnostics. It was founded in 2009 with the goal of developing and commercializing innovative solutions for cancer diagnosis. The business model of OncoCyte Corp is based on the development and marketing of diagnostic tests for various types of cancer. The company focuses on identifying biomarkers that enable accurate and reliable diagnosis. The tests developed by OncoCyte Corp can be used for both early detection and monitoring of cancer patients. OncoCyte Corp is divided into several divisions, each specialized in developing products for specific types of cancer. These divisions include breast cancer, lung cancer, bladder cancer, and ovarian cancer. Each division is led by an expert team with extensive knowledge and experience in the respective area. One of the key products of OncoCyte Corp is the DetermaRx™ test, specifically developed for lung cancer. This test identifies specific biomarkers that provide a prognosis regarding the response to chemotherapy. The DetermaRx™ test is currently in clinical trials and could be used in the future to aid in the decision-making process for selecting the appropriate treatment method for lung cancer patients. Another product of OncoCyte Corp is the DetermaDx™ test, specifically developed for the early detection of breast cancer. This test utilizes a combination of biomarker-based tests and imaging techniques to detect cancer cells at an early stage. The DetermaDx™ test is currently undergoing validation and could potentially become a standard diagnosis for breast cancer in the future. OncoCyte Corp has also formed several partnerships with pharmaceutical and diagnostic companies to promote the development and commercialization of its products. One such partnership exists with Life Technologies Corporation, a globally leading company in the field of diagnostics and analytics. OncoCyte Corp strives to develop and bring to market innovative solutions for cancer diagnosis. With its vast resources and experienced team of scientists, the company has the potential to change the way cancer is diagnosed and treated. OncoCyte ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding OncoCyte's P/S Ratio
OncoCyte's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing OncoCyte's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating OncoCyte's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in OncoCyte’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about OncoCyte Stock
How has the price-earnings ratio of OncoCyte changed compared to last year?
The price-to-earnings ratio of OncoCyte has increased by -41.46% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of OncoCyte high compared to other companies?
Yes, the price-to-earnings ratio of OncoCyte is high compared to other companies.
How does an increase in the price-earnings ratio of OncoCyte affect the company?
An increase in the price-earnings ratio of OncoCyte would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of OncoCyte affect the company?
A decrease in the price-earnings ratio of OncoCyte would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of OncoCyte?
Some factors that influence the price-earnings ratio of OncoCyte are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does OncoCyte pay?
Over the past 12 months, OncoCyte paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, OncoCyte is expected to pay a dividend of 0 USD.
What is the dividend yield of OncoCyte?
The current dividend yield of OncoCyte is .
When does OncoCyte pay dividends?
OncoCyte pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of OncoCyte?
OncoCyte paid dividends every year for the past 0 years.
What is the dividend of OncoCyte?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is OncoCyte located?
OncoCyte is assigned to the 'Health' sector.
Wann musste ich die Aktien von OncoCyte kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of OncoCyte from 7/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/2/2024.
When did OncoCyte pay the last dividend?
The last dividend was paid out on 7/2/2024.
What was the dividend of OncoCyte in the year 2023?
In the year 2023, OncoCyte distributed 0 USD as dividends.
In which currency does OncoCyte pay out the dividend?
The dividends of OncoCyte are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von OncoCyte
Our stock analysis for OncoCyte Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of OncoCyte Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
